Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
ReplyCorrespondence

Dr. Pagnoux, et al reply

CHRISTIAN PAGNOUX, MURIEL STUBBE and LOÏC GUILLEVIN
The Journal of Rheumatology October 2011, 38 (10) 2269; DOI: https://doi.org/10.3899/jrheum.110494
CHRISTIAN PAGNOUX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: christian.pagnoux@cch.aphp.fr
MURIEL STUBBE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LOÏC GUILLEVIN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

To the Editor:

We appreciate the comments by Drs. Garcia-Valladares and Espinoza1 regarding our study on granulomatosis with polyangiitis (Wegener’s, GPA) persistently localized to one organ2.

As emphasized by their patient’s case, subglottic stenosis often evolves and can relapse as a limited process in GPA, in the absence of or with only a few other active systemic extra-respiratory tract vasculitis manifestation(s) and/or progress to fibrotic stenosis. Most of these patients with this potentially rapidly life-threatening manifestation represent a difficult therapeutic challenge3. Because the response of subglottic stenosis to conventional systemic treatments is, at best, partial and, if so, often only transient, local therapy, mainly based on repeated dilations with or without local injections of corticosteroids, represents the cornerstone of its therapeutic management4,5. The places of tracheal surgery, laser deobstruction, and local injections of other drugs, such as mitomycin, are still being debated and/or must be better analyzed5,6.

We have also treated and reported several patients with GPA and subglottic and/or bronchial stenoses. Among the 494 patients entered in the French Vasculitis Study Group database at the time of our analysis, we identified 12 patients with subglottic stenosis, but they also had other disease manifestations, concomitantly and/or later during the course of their disease. In 2 of them, however, the other disease manifestations were “limited” to crusting rhinitis or nondestructive sinus involvement on computerized tomography scans and not always symptomatic or active when subglottic stenosis required therapeutic intervention. As stated in our Methods, and unlike the study by Holle, et al7, we excluded patients who had upper and lower respiratory tract involvement, regardless of the time they occurred for each of these 2 sites during followup. Whether upper (i.e., nose and sinuses) and lower (i.e., trachea, and perhaps main bronchi) respiratory tracts, excluding more distal bronchi and lung parenchyma, should have been considered a single organ [i.e., corresponding to ear-nose-throat (ENT) involvement] was and remains debatable for our study. In addition, a diagnosis of GPA for antineutrophil cytoplasmic antibody-negative patients with subglottic stenosis as the sole manifestation and no histological evidence of vasculitis remains uncertain, with alternative diagnoses being restricted to atrophic polychondritis, amyloidosis, cancer, and primary (congenital or idiopathic and progressive) or secondary tracheomalacia (after endotracheal intubation, infection, e.g., tuberculosis, mechanical, thermal or caustic injuries, or external trauma). Sarcoidosis can also affect the larynx, but usually in its supraglottic region.

Finally, rituximab has already been used to treat subglottic stenosis in several patients with GPA, often with good, but inconsistent, results. In our experience and as reported by Aries et al8 it should be noted that the therapeutic response to rituximab for this specific manifestation may be quite long in coming, compared to responses of some other manifestations, like arthritis, pauci-immune glomerulonephritis, or alveolar hemorrhage9. Optimal management of these rare but severe and challenging patients with subglottic and/or bronchial stenoses must be multidisciplinary, with ENT specialists and/or respirologists for local followup and therapy, and rheumatologists and/or internists to handle conventional systemic treatments, knowing their relatively limited, transient and/or partial efficacies, especially when subglottic stenosis is due to fibrosis. Hopefully, other agents under investigation or to be identified will further help treat this manifestation.

REFERENCES

  1. 1.↵
    1. Garcia-Valladares I,
    2. Espinoza LR
    . Subglottic stenosis is a form of limited Wegener’s granulomatosis. J Rheumatol 2011;38:2268.
    OpenUrlFREE Full Text
  2. 2.↵
    1. Pagnoux C,
    2. Stubbe M,
    3. Lifermann F,
    4. Decaux O,
    5. Pavic M,
    6. Bérezné A,
    7. et al.
    Wegener’s granulomatosis strictly and persistently localized to one organ is rare: assessment of 16 patients from the French Vasculitis Study Group database. J Rheumatol 2011;38:475–8.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Hervier B,
    2. Pagnoux C,
    3. Renaudin K,
    4. Masseau A,
    5. Pottier P,
    6. Planchon B,
    7. et al.
    Endobronchial stenosis in Wegener’s granulomatosis [French]. Rev Méd Interne 2006;27:453–7.
    OpenUrl
  4. 4.↵
    1. Waxman J,
    2. Bose WJ
    . Laryngeal manifestations of Wegener’s granulomatosis: case reports and review of the literature. J Rheumatol 1986;13:408–11.
    OpenUrlPubMed
  5. 5.↵
    1. Langford CA,
    2. Sneller MC,
    3. Hallahan CW,
    4. Hoffman GS,
    5. Kammerer WA,
    6. Talar-Williams C,
    7. et al.
    Clinical features and therapeutic management of subglottic stenosis in patients with Wegener’s granulomatosis. Arthritis Rheum 1996;39:1754–60.
    OpenUrlPubMed
  6. 6.↵
    1. Hernandez-Rodriguez J,
    2. Hoffman GS,
    3. Koening CL
    . Surgical interventions and local therapy for Wegener’s granulomatosis. Curr Opin Rheumatol 2010;22:29–36.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Holle JU,
    2. Gross WL,
    3. Holl-Ulrich K,
    4. Ambrosch P,
    5. Noelle B,
    6. Both M,
    7. et al.
    Prospective long-term follow-up of patients with localised Wegener’s granulomatosis: does it occur as persistent disease stage? Ann Rheum Dis 2010;69:1934–9.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Aries PM,
    2. Hellmich B,
    3. Voswinkel J,
    4. Both M,
    5. Nolle B,
    6. Holl-Ulrich K,
    7. et al.
    Lack of efficacy of rituximab in Wegener’s granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 2006;65:853–8.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Aouba A,
    2. Pagnoux C,
    3. Bienvenu B,
    4. Mahr A,
    5. Guillevin L
    . Analysis of Wegener’s granulomatosis responses to rituximab: current evidence and therapeutic prospects. Clin Rev Allergy Immunol 2008;34:65–73.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 38, Issue 10
1 Oct 2011
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Dr. Pagnoux, et al reply
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Dr. Pagnoux, et al reply
CHRISTIAN PAGNOUX, MURIEL STUBBE, LOÏC GUILLEVIN
The Journal of Rheumatology Oct 2011, 38 (10) 2269; DOI: 10.3899/jrheum.110494

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Dr. Pagnoux, et al reply
CHRISTIAN PAGNOUX, MURIEL STUBBE, LOÏC GUILLEVIN
The Journal of Rheumatology Oct 2011, 38 (10) 2269; DOI: 10.3899/jrheum.110494
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • REFERENCES
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Dr. Putman et al reply
  • Drs. Chung and McMahan reply
  • Drs. Meer and Ogdie reply
Show more Correspondence

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire